A new study has found that the drug Axitnib may delay the development of kidney cancer for longer than other treatments, according to researchers from the Cleveland Clinic.

Compared to another drug, Sorafenib, Axitnib was more effective in preventing disease progression of renal cell carcinoma, the most prevalent form of kidney cancer.

“There was a two-month advantage to Axitnib to Sorafenib in this setting,” said lead researcher Dr. Brian Rini, an oncologist at the Cleveland Clinic’s Taussig Cancer Institute.

Rini said the information will allow oncologists to build a better treatment plan for certain kidney cancer patients.

“What makes people feel bad with cancer is tumor-burden causing fatigue and lack of appetite or sometimes pain,” he said. “So, by delaying the time until worsening, you are in essence buying time without symptoms.”

The study was published in the journal Lancet.